Scholars Central

EditorialPublished 26 Sep 2015

Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: A Different Perspective

Authors: Richard T Silver, Hans Carl Hasselbalch

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recent publications have de-emphasized the importance of recombinant interferon alpha (rIFNα) for the treatment of polycythemia vera (PV) or essential thrombocythemia (ET), favoring the use of phlebotomy and/or hydroxyurea. Here we express our reasons for the use of rIFNα early in the course of PV or ET in the absence of a phase 3 trial.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Blood Research & Hematologic Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Research & Hematologic Diseases
  • SubjectHaematology
  • BylineArticles whose byline prints “Richard T Silver”
  • BylineArticles whose byline prints “Hans Carl Hasselbalch”